iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 2,500 shares of the stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $90.94, for a total value of $227,350.00. Following the transaction, the chief executive officer directly owned 2,202,500 shares in the company, valued at approximately $200,295,350. This represents a 0.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Stock Up 1.1%
IRMD stock opened at $90.14 on Thursday. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of 51.51 and a beta of 1.11. iRadimed Corporation has a 52-week low of $50.00 and a 52-week high of $107.90. The stock's fifty day simple moving average is $98.37 and its 200-day simple moving average is $93.49.
iRadimed (NASDAQ:IRMD - Get Free Report) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The firm had revenue of $22.69 million during the quarter, compared to analyst estimates of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, analysts anticipate that iRadimed Corporation will post 1.94 earnings per share for the current fiscal year.
iRadimed Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Stockholders of record on Monday, February 23rd were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Monday, February 23rd. This is an increase from iRadimed's previous quarterly dividend of $0.17. iRadimed's payout ratio is currently 45.71%.
Analyst Ratings Changes
A number of research firms recently issued reports on IRMD. Weiss Ratings restated a "buy (b-)" rating on shares of iRadimed in a report on Monday, December 29th. Roth Mkm reaffirmed a "buy" rating and set a $120.00 price target on shares of iRadimed in a research note on Tuesday, February 10th. Lake Street Capital reiterated a "buy" rating and issued a $120.00 price target on shares of iRadimed in a report on Wednesday, February 11th. Finally, Freedom Capital raised shares of iRadimed to a "strong-buy" rating in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $120.00.
Read Our Latest Stock Report on IRMD
Institutional Trading of iRadimed
A number of institutional investors and hedge funds have recently bought and sold shares of IRMD. CWM LLC raised its position in iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 211 shares during the period. Quarry LP purchased a new stake in shares of iRadimed in the third quarter worth about $40,000. Farther Finance Advisors LLC grew its stake in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 397 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 495 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new stake in shares of iRadimed during the 3rd quarter valued at about $47,000. Institutional investors and hedge funds own 92.34% of the company's stock.
About iRadimed
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
